Jessica L Conway1, Joseph M Connors2, Scott Tyldesley1, Kerry J Savage2, Belinda A Campbell3, Yvonne Y Zheng4, Jeremy Hamm4, Tom Pickles5. 1. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada. 2. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 3. Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 4. Department of Cancer Surveillance and Outcomes, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 5. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: TPickles@bccancer.bc.ca.
Abstract
PURPOSE: To determine whether the risk of secondary breast cancer (SBC) is reduced in women with Hodgkin lymphoma (HL) treated with smaller field radiation therapy (SFRT) versus mantle field radiation therapy (MRT). METHODS AND MATERIALS: We used the BC Cancer Agency (BCCA) Lymphoid Cancer Database to identify female patients treated for HL between January 1961 and December 2009. Radiation therapy volumes were categorized as MRT or SFRT, which included involved field, involved site, or involved nodal radiation therapy. SBC risk estimates were compared using competing risk analysis and Fine and Gray multivariable model: MRT ± chemotherapy, SFRT ± chemotherapy, or chemotherapy-only. RESULTS: Of 734 eligible patients, 75% of the living patients have been followed up for more than 10 years, SBC has developed in 54, and 15 have died of breast cancer. The 20-year estimated risks (competing risk cumulative incidence) for SBC differed significantly: MRT 7.5% (95% confidence interval [CI] 4.4%-11.5%), SFRT 3.1% (95% CI 1.0%-7.7%), and chemotherapy-only 2.2% (95% CI 1.0%-4.8%) (P=.01). Using a Fine and Gray model to control for death and patients lost to follow-up, MRT was associated with a higher risk of SBC (hazard ratio [HR] = 2.9; 95% CI 1.4%-6.0%; P=.004) compared with chemotherapy-only and with SFRT (HR = 3.3; 95% CI 1.3%-8.4%; P=.01). SFRT was not associated with a greater risk of SBC compared with chemotherapy-only (HR = 0.87; 95% CI 0.28%-2.66%; P=.80). CONCLUSION: This study confirms that large-volume MRT is associated with a markedly increased risk of SBC; however, more modern small-volume RT is not associated with a greater risk of SBC than chemotherapy alone. Crown
PURPOSE: To determine whether the risk of secondary breast cancer (SBC) is reduced in women with Hodgkin lymphoma (HL) treated with smaller field radiation therapy (SFRT) versus mantle field radiation therapy (MRT). METHODS AND MATERIALS: We used the BC Cancer Agency (BCCA) Lymphoid Cancer Database to identify female patients treated for HL between January 1961 and December 2009. Radiation therapy volumes were categorized as MRT or SFRT, which included involved field, involved site, or involved nodal radiation therapy. SBC risk estimates were compared using competing risk analysis and Fine and Gray multivariable model: MRT ± chemotherapy, SFRT ± chemotherapy, or chemotherapy-only. RESULTS: Of 734 eligible patients, 75% of the living patients have been followed up for more than 10 years, SBC has developed in 54, and 15 have died of breast cancer. The 20-year estimated risks (competing risk cumulative incidence) for SBC differed significantly: MRT 7.5% (95% confidence interval [CI] 4.4%-11.5%), SFRT 3.1% (95% CI 1.0%-7.7%), and chemotherapy-only 2.2% (95% CI 1.0%-4.8%) (P=.01). Using a Fine and Gray model to control for death and patients lost to follow-up, MRT was associated with a higher risk of SBC (hazard ratio [HR] = 2.9; 95% CI 1.4%-6.0%; P=.004) compared with chemotherapy-only and with SFRT (HR = 3.3; 95% CI 1.3%-8.4%; P=.01). SFRT was not associated with a greater risk of SBC compared with chemotherapy-only (HR = 0.87; 95% CI 0.28%-2.66%; P=.80). CONCLUSION: This study confirms that large-volume MRT is associated with a markedly increased risk of SBC; however, more modern small-volume RT is not associated with a greater risk of SBC than chemotherapy alone. Crown
Authors: Rebecca H Johnson; Carey K Anders; Jennifer K Litton; Kathryn J Ruddy; Archie Bleyer Journal: Pediatr Blood Cancer Date: 2018-08-28 Impact factor: 3.167
Authors: Georgios Ntentas; Katerina Dedeckova; Michal Andrlik; Marianne C Aznar; Rebecca Shakir; Johanna Ramroth; Rubina Begum; Jiří Kubeš; Sarah C Darby; N George Mikhaeel; David J Cutter Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-09 Impact factor: 7.038
Authors: B S Hoppe; C E Hill-Kayser; Y D Tseng; S Flampouri; H M Elmongy; O Cahlon; N P Mendenhall; A Maity; L A McGee; J P Plastaras Journal: Ann Oncol Date: 2017-09-01 Impact factor: 32.976
Authors: Laura Ann Rechner; Arezoo Modiri; Line Bjerregaard Stick; Maja V Maraldo; Marianne C Aznar; Stephanie R Rice; Amit Sawant; Søren M Bentzen; Ivan Richter Vogelius; Lena Specht Journal: Acta Oncol Date: 2020-03-27 Impact factor: 4.089
Authors: Chelsea C Pinnix; Jillian R Gunther; Penny Fang; Mikaela E Bankston; Sarah A Milgrom; David Boyce; Hun Ju Lee; Ranjit Nair; Raphael Steiner; Paolo Strati; Sairah Ahmed; Swaminathan P Iyer; Jason Westin; Simrit Parmar; M Alma Rodriguez; Loretta Nastoupil; Sattva Neelapu; Christopher Flowers; Bouthaina S Dabaja Journal: JAMA Netw Open Date: 2020-09-01